本帖最后由 老马 于 2013-3-13 13:43 编辑 % U$ ]# H" G8 I2 n# e* u6 _
, m1 x; X. F. s5 K5 A+ y
健择（吉西他滨）+顺铂+阿瓦斯汀
$ s$ N8 c) p% t4 c. A Gemzar +Cisplatin + Avastin2 h9 y7 C0 Z g- t& R4 _$ P5 d
http://annonc.oxfordjournals.org/content/21/9/1804.full9 g$ E' \2 H& i; ^" z: u# u
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) " z( Y R- z0 N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
! O* i; u& t, Z; X! J9 xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, N% T$ t9 d# g% ]6 p$ s
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 497)
, y" X- S0 q. T! {8 K6 Q华为网盘附件：
! Q1 U. t7 ^. O% U1 d+ t7 l【华为网盘】ava.JPG
& Q9 h8 Z4 {" A0 i2 ]0 U |
显身卡
